As of Sep 17 2014 4:00PM
Minimum 20 minute delay
  • 9/17/2014 4:01:01 PM

    Covidien Announces Dividend Increase

    DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 17, 2014-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 13% increase in the quarterly dividend rate, from $0.32 per ordinary share to $0.36 per ordinary share. “This increase is consistent with our Board’s stated objective of moving to a higher payout ratio and…
  • 9/15/2014 7:00:54 AM

    Covidien Announces Start of Enrollment in Two Neurovascular Clinical Trials

    DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 15, 2014-- Covidien plc announced today the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the company’s advanced neurovascular solutions. …
  • 8/28/2014 7:00:41 AM

    Covidien Acquires Venous Disease Treatment Developer Sapheon, Inc.

    Transaction expands Covidien’s market leading portfolio with next generation technology for treatment of varicose veins DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 28, 2014-- Covidien plc (NYSE: COV) today announced that it has acquired …

A Partner in Health

Collaborating with physicians and other healthcare professionals, focusing on research and development and maintaining clinical leadership add up to innovative medical solutions that make a difference.

Conscientious Collaboration

Ensuring ethical interactions with healthcare professionals is vital to the global healthcare environment. Covidien’s Conscientious Collaboration platform is our commitment to open communications about the need to ensure compliant interactions with our customers and partners.

One Covidien

One look. One Covidien. Experience the new unified look of Covidien. Easy-to-use labeling. New outside packaging with the same quality products inside. First-class service and support.

Visit Us